Table 1. Clinical and pathologic characteristics of the 43 patients (Whole Exome Sequencing).
| Study ID | Patient Age (At Surgery) |
Gender | Prior NMIBC |
Pathologic T | Pathologic N | Histologic Type | Adjuvant Chemotherapy |
Recurrence | Location of Recurrence | Time to recurrence (Months) |
Length of follow up (Months) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A1 | 78 | M | NO | pT3b | pN0 | squamous carcinoma | NO | NO | N/A | N/A | 59.6 |
| A2 | 57 | M | YES | pT2b | pN0 | urothelial carcinoma with squamous differentiation | NO | NO | N/A | N/A | 35.7 |
| A3 | 80 | M | NO | pT4a | pN0 | adenocarcinoma | NO | YES | pelvic mass, lungs | 9.4 | N/A |
| A4 | 62 | M | NO | pT3a | pN0 | urothelial carcinoma | NO | YES | liver, bones | 16.4 | N/A |
| A5 | 55 | F | NO | pT2b | pN0 | urothelial carcinoma with squamous differentiation | NO | NO | N/A | N/A | 25.6 |
| A6 | 72 | F | Unknown | pT4a | pN0 | adenocarcinoma | NO | YES | lungs, stomach | 1.4 | N/A |
| A7 | 79 | M | NO | pT3a | pN0 | urothelial carcinoma | NO | NO | N/A | N/A | 47.3 |
| A8 | 70 | M | NO | pT3b | pN0 | urothelial carcinoma | NO | YES | pelvic mass | 5.3 | N/A |
| A9 | 54 | F | Yes | pT2b | pN0 | urothelial carcinoma | NO | NO | N/A | N/A | 42.5 |
| A10 | 73 | M | Yes | pT3a | pN0 | urothelial carcinoma | NO | YES | retroperitoneal nodes, lungs | 7.1 | N/A |
| A11 | 55 | M | NO | pT2a | pN0 | urothelial carcinoma | NO | YES | pelvic mass/lungs/liver/bones | 14.4 | N/A |
| A12 | 67 | M | Unknown | pT2b | pN0 | urothelial carcinoma with squamous differentiation | NO | NO | N/A | N/A | 32.4 |
| A13 | 67 | F | NO | pT3a | pN0 | urothelial carcinoma | NO | YES | liver, bones | 2.5 | N/A |
| A14 | 68 | F | YES | pT3a | pN0 | urothelial carcinoma | NO | NO | N/A | N/A | 40.4 |
| A15 | 74 | M | NO | pT4a | pN0 | urothelial carcinoma | NO | NO | N/A | N/A | 43.4 |
| A16# | 72 | M | YES | pT3a | pN0 | urothelial carcinoma | NO | NO | N/A | N/A | 23.2 |
| A17 | 59 | M | NO | pT3b | pN0 | urothelial carcinoma | NO | NO | N/A | N/A | 37.1 |
| A18 | 59 | F | YES | pT3a | pN0 | urothelial carcinoma with squamous differentiation | NO | NO | N/A | N/A | 33.8 |
| A19 | 50 | M | NO | pT3b | pN0 | urothelial carcinoma | YES | YES | pelvic mass | 5.4 | N/A |
| A20 | 64 | M | YES | pT3a | pN1 | urothelial carcinoma | YES | NO | N/A | N/A | 53.9 |
| A21 | 43 | F | YES | pT2b | pN0 | urothelial carcinoma with squamous differentiation | NO | NO | N/A | N/A | 13.9 |
| A22 | 65 | M | YES | pT3b | pN1 | urothelial carcinoma | YES | YES | pelvic mass/lungs/liver/bones | 6.9 | N/A |
| A23 | 69 | M | NO | pT3b | pN0 | urothelial carcinoma | NO | YES | lungs | 5.8 | N/A |
| A24 | 74 | F | YES | pT3a | pN0 | urothelial carcinoma | NO | YES | lungs | 7.9 | N/A |
| A25 | 59 | M | NO | pT2b | pN0 | urothelial carcinoma with squamous differentiation | NO | NO | N/A | N/A | 21.8 |
| A26 | 55 | M | NO | pT3a | pN0 | urothelial carcinoma | NO | NO | N/A | N/A | 14.8 |
| A27 | 59 | M | NO | pT4a | pN2 | urothelial carcinoma | NO | YES | retroperitoneal nodes/lungs/liver/bones | 1.5 | N/A |
| A28 | 57 | M | NO | pT3a | pN1 | urothelial carcinoma | YES | YES | pelvic mass, sigmoid colon | 6.9 | N/A |
| A29 | 84 | M | NO | pT3a | pN0 | urothelial carcinoma with squamous differentiation | NO | NO | N/A | N/A | 14.9 |
| A30 | 45 | M | NO | pT4 | pN2 | urothelial carcinoma | YES | YES | retroperitoneal and mesenteric nodes, small bowel | 11.0 | N/A |
| A31# | 71 | M | NO | pT2a | pN0 | urothelial carcinoma | NO | NO | N/A | N/A | 12.7 |
| A32 | 77 | M | NO | pT2a | pN0 | urothelial carcinoma | NO | YES | pelvic mass, liver | 43.3 | N/A |
| A33 | 68 | M | NO | pT3a | pN1 | urothelial carcinoma | YES | YES | unknown sites | 3.9 | N/A |
| A34 | 56 | M | NO | pT3a | pN0 | urothelial carcinoma | NO | NO | N/A | N/A | 12.2 |
| A35 | 71 | F | NO | pT2b | pN2 | urothelial carcinoma | YES | NO | N/A | N/A | 39.7 |
| A36 | 59 | M | NO | pT4 | pN0 | squamous carcinoma | YES | YES | retroperitoneal nodes | 1.1 | N/A |
| A37 | 73 | M | NO | pT4 | pN0 | urothelial carcinoma | YES | NO | N/A | N/A | 45.3 |
| A38 | 79 | M | NO | pT3a | pN2 | urothelial carcinoma | YES | YES | mediastinal nodes, pelvic mass | 26.3 | N/A |
| A39 | 62 | M | NO | pT3a | pN2 | urothelial carcinoma | YES | YES | retroperitoneal nodes, liver, bones | 31.6 | N/A |
| A40 | 52 | M | NO | pT3b | pN1 | urothelial carcinoma with squamous differentiation | YES | NO | N/A | N/A | 46.2 |
| A41 | 68 | F | NO | pT3b | pN2 | urothelial carcinoma | YES | NO | N/A | N/A | 37.5 |
| A42 | 82 | M | NO | pT2 | pN0 | urothelial carcinoma with neuroendocrine features | NO | NO | N/A | N/A | 21.9 |
| A43 | 79 | M | Unknown | pT2a | pN0 | urothelial carcinoma | NO | NO | N/A | N/A | 6.6 |
| Median age= 67 Range (43-84) |
%M= 76.7 %F= 23.3 |
% prior NMIBC= 23.2% |
% pT2=27.9 % pT3=55.8 %pT4=16.3 |
% pN(+)= 25.6 % pN(-)= 74.4 |
Median time to recurrence= 6.9 |
See footnote* |
*
Median length of follow-up for non-recurrent cases = 34.7 months. Length of follow-up is defined as the difference between the date of surgery and the last clinic visit. Length of follow-up is calculated only for patients without recurrence to demonstrate the length of the intervals for these patients without evidence of disease recurrence (NED). Patients with recurrent disease met the primary study endpoint at the time of recurrence, and therefore length of follow-up in these patients is not applicable. NMIBC= non-muscle invasive bladder cancer.
#
excluded from mutational profile and clinical outcomes correlation since, although patient had no evidence of documented disease recurrence, patient died shortly after last follow-up of unknown causes and it could not be excluded that death was related to disease recurrence.